Identifying the steps required to effectively implement next-generation sequencing in oncology at a national level in Europe

Horgan, Denis (avtor), Čufer, Tanja (avtor)

Next-generation sequencing (NGS) may enable more focused and highly personalized cancer treatment, with the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines now recommending NGS for daily clinical practice for several tumor types. However, NGS implementation, and therefore patient access, varies across Europe; a multi-stakeholder collaboration is needed to establish the conditions required to improve this discrepancy. In that regard, we set up European Alliance for Personalised Medicine (EAPM)-led expert panels during the first half of 2021, including key stakeholders from across 10 European countries covering medical, economic, patient, industry, and governmental expertise. We describe the outcomes of these panels in order to define and explore the necessary conditions for NGS implementation into routine clinical care to enable patient access, identify specific challenges in achieving them, and make short- and long-term recommendations. The main challenges identified relate to the demand for NGS tests (governance, clinical standardization, and awareness and education) and supply of tests (equitable reimbursement, infrastructure for conducting and validating tests, and testing access driven by evidence generation). Recommendations made to resolve each of these challenges should aid multi-stakeholder collaboration between national and European initiatives, to complement, support, and mutually reinforce efforts to improve patient care.

• Jezik: Angleški jezik
• Ključne besede: clinical standardization, equitable reimbursement, European Alliance for Personalised Medicine, Europe’s Beating Cancer Plan, evidence generation, governance, molecularly guided treatment options, next-generation sequencing, stakeholder awareness and education, testing infrastructure
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2022
• Št. strani: 27 str.
• Številčenje: Vol. 12, iss. 1, art. 72
• PID: 20.500.12556/RUL-137400
• ISSN pri članku: 2075-4426
• DOI: 10.3390/jpm12010072
• COBISS.SI-ID: 140518403
• Datum objave v RUL: 16.06.2022

Gradivo je del revije

• Naslov: Journal of personalized medicine
• Skrajšan naslov: J. pers. med.
• Založnik: MDPI
• ISSN: 2075-4426
• COBISS.SI-ID: 31207641

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: klinična standardizacija, pravično povračilo, Evropska zveza za personalizirano medicino, Evropski načrt za premagovanje raka, pridobivanje dokazov, upravljanje, molekularno vodene možnosti zdravljenja, sekvenciranje naslednje generacije, ozaveščanje in izobraževanje deležnikov, testiranje infrastrukture